JBSS 39.38 John B. Sanfilippo & Son $JBSS Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:02 AM

JBSS 39.38 John B. Sanfilippo & Son $JBSS Hit a 52 week high of 39.38 Closing the day 09:30 at 39.38 -0.05 -0.13% With a day low of 39.38 and a total volume of 608.

JBSS Recent Posts: http://investorshangout.com/Sanfilippo-John-B...BSS-54529/

JBSS John B. Sanfilippo & Son Recent Headline News

John B. Sanfilippo & Son, Inc. to Present at the Southwest IDEAS Investor Conference on November 19th & 20th in Dallas
Business Wire - Thu Nov 13, 4:13PM CST
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), today announced that Mike Valentine, Chief Financial Officer and Frank Pellegrino, Sr. Vice President of Finance will present at the Southwest IDEAS Investor Conference on Thursday, November 20, 2014 at the Marriott - Quorum Hotel in Addison, Texas. John B. Sanfilippo & Son, Inc.'s presentation is scheduled to begin at 1:50 p.m. Central. The presentation will be webcast live and may be accessed at the conference website, www.IDEASConferences.com, or in the investor relations section of the company's website: http://www.jbssinc.com.
JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son declares $1.50 dividend
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:47PM CDT

JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son, Inc. Board Declares Special Cash Dividend of $1.50 per share of Common Stock and $1.50 per share of Class A Common Stock
Business Wire - Tue Oct 28, 4:04PM CDT
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the "Company"

today announced that its Board of Directors (the "Board"

declared a special cash dividend (the "Dividend"

of $1.50 per share on all issued and outstanding shares of Common Stock of the Company and $1.50 per share on all issued and outstanding shares of Class A Common Stock of the Company.
JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son Is A Strong Buy For Long Term Investors
Jaxon Research - at Seeking Alpha - Tue Oct 28, 10:24AM CDT

JBSS: 39.41 (-0.02)

Update: John B. Sanfilippo & Son's Weak Fiscal Q1'15
Marshall Hargrave - at Seeking Alpha - Tue Oct 28, 1:55AM CDT

JBSS: 39.41 (-0.02)

John B Sanfilippo & Son's (JBSS) CEO Jeffrey Sanfilippo on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:50PM CDT

JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son EPS of $0.53
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:27PM CDT

JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son, Inc. Net Sales Increased by 16% on Higher Pricing and Strong Sales Volume
Business Wire - Thu Oct 23, 3:10PM CDT
--Net sales increased by 16.0%
JBSS: 39.41 (-0.02)

Shares of JBSS Up 43.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 20, 9:09AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 6 months, John B. Sanfilippo & Son has returned 43.68% as of today's recent price of $35.03.
JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son, Inc. 1st Quarter Fiscal 2015 Operating Results Conference Call
GlobeNewswire - Fri Oct 17, 4:00PM CDT
John B. Sanfilippo & Son, Inc. (Nasdaq:JBSS), a major processor and distributor of snack and recipe nut products, will hold its quarterly conference call to discuss first quarter fiscal 2015 operating results on Friday, October 24, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). First quarter fiscal 2015 results are expected to be released after the market closes on Thursday, October 23, 2014.
JBSS: 39.41 (-0.02)

Today In SA PRO: Tuesday, October 14
SA PRO Top Ideas - at Seeking Alpha - Wed Oct 15, 4:00AM CDT
Outstanding Performance Award Winner #1: Top Short Idea on MCHX (Marchex, Inc.) by Ariana Research, published July 11, 2014. Return to date: +68% (See author update » ) Outstanding Performance Award Winner #2: PRO Short Idea on ITT...
WATT: 9.58 (+0.32), JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son Has Returned 34.3% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Fri Oct 10, 5:11PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 34.33% as of today's recent price of $32.75.
JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son Up 32.9% Since SmarTrend Uptrend Call (JBSS)
Comtex SmarTrend(R) - Fri Oct 03, 4:45PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.90% as of today's recent price of $32.40.
JBSS: 39.41 (-0.02)

Fisher Announces Statewide Campaign and $40,000 Donation to Feeding Texas
PR Newswire - Fri Oct 03, 9:00AM CDT
Fisher® Nuts announced a statewide campaign to bring Texas communities together to help feed hungry families this holiday season. In its third year partnering with Feeding Texas (formerly the Texas Food Bank Network) for the Fisher Shares & Cares campaign, Fisher is donating $40,000 that will be used to help feed 400,000 Texans throughout the season.
JBSS: 39.41 (-0.02)

33.6% Return Seen to Date on SmarTrend John B. Sanfilippo & Son Call (JBSS)
Comtex SmarTrend(R) - Fri Sep 26, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 33.55% as of today's recent price of $32.56.
JBSS: 39.41 (-0.02)

Shares of JBSS Up 32.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 9:36AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.32% as of today's recent price of $32.26.
JBSS: 39.41 (-0.02)

Uptrend Call Working As John B. Sanfilippo & Son Stock Rises 33.0% (JBSS)
Comtex SmarTrend(R) - Fri Sep 12, 9:10AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 32.98% as of today's recent price of $32.42.
JBSS: 39.41 (-0.02)

Fisher Nuts and Chef Alex Guarnaschelli Announce Second Annual "My Fresh Twist" Recipe Contest
PR Newswire - Tue Sep 09, 10:45AM CDT
Fisher® Nuts has announced the second annual "My Fresh Twist" recipe contest today. Beginning now through October 21, 2014 consumers are invited to submit an original recipe using walnuts, almonds or pecans to www.myfreshtwist.com for a chance to win a grand prize that includes a trip for two to New York City to meet Chef Alex Guarnaschelli.
JBSS: 39.41 (-0.02)

John B. Sanfilippo & Son Has Returned 27.8% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Thu Aug 28, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 27.75% as of today's recent price of $31.15.
JBSS: 39.41 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...